Brown-Forman ( BF.B) rated new Buy at Citigroup. $67 price target. Company is positioned to see accelerating sales growth.

Cisco Systems ( CSCO) rated new Equal-weight at Morgan Stanley. Market share losses could offset growth from new ventures.

Genzyme ( GENZ) downgraded at Barclays to Equal Weight from Overweight and price target cut to $52 from $63. Persistent Overhang on consent Decree, Barclays said. 2010 and 2011 EPS estimates lowered to $2.31 and $3.68, respectively.

Generac ( GNRC) rated new Neutral at Goldman. $17 price target. Company has dominant market share in the residential market and generates significant free cash flow.

Juniper Networks ( JNPR) rated new Overweight at Morgan Stanley. JNPR was initiated with an Overweight rating. $37 price target. Ethernet switching market should drive sales and earnings growth.

RTI International Metals ( RTI) downgraded at BofA/Merrill to Underperform from Neutral. Valuation call, Bank of America/Merrill Lynch said. Price target raised to $32 from $24. Maintain 2010 and 2011 EPS estimates at -$0.60 and $0.30, respectively.

Westlake Chemical ( WLK) upgraded at JP Morgan. Rating raised to Overweight from Neutral. Price target raised to $28 from $21. Maintains 2010 EPS estimates of $1.50.


Archer Daniels Midland ( ADM) target, estimates cut at BofA/Merrill. ADM price target lowered to $34 from $37 as ethanol sentiment is driving stock weakness. 2010 and 2011 EPS estimates both lowered to $2.90. Maintain Buy rating.

Apollo Group ( APOL) target, estimates higher at BofA/Merrill. APOL 2010 and 2011 EPS estimates increased to $5.10 and $5.93, respectively. Strategic shift continues. Price target raised by a dollar to $69. Maintain Neutral rating.

Apollo ( APOL) estimates lowered at UBS through 2011. Company lowered guidance. Buy rating and $120 price target.

Avnet ( AVT) estimates, target raised at UBS. AVT estimates were increased through 2011. Company pre-announced earnings and should also benefit from the BELM acquisition. Buy rating and new $35 price target.

Chubb ( CB) estimates lowered at UBS through 2011. Company is seeing higher catastrophe losses. Buy rating and $56 price target.

Celgene ( CELG) target boosted at Citigroup. Shares of CELG now seen reaching $72. Company could deliver higher Revlimid growth in Europe. Buy rating.

FMC Corp. ( FMC) target raised at UBS to $70. Higher spot commodity prices are helping contract pricing. Buy rating.

Google ( GOOG) estimates boosted at UBS through 2011. Channel checks are showing positive keyword pricing. Buy rating and $700 price target.
Who Owns Google?

Goldman Sachs ( GS) 2010 and 2011 estimates boosted at Barclays to $18.28 and $20.23, respectively. Raising out FICC and principal investment gains estimates. Maintain Equal weight rating and $95 price target.

Mead Johnson ( MJN) numbers increased at Citigroup through 2012. Company is growing market share and the developing markets outlook is robust. Buy rating and new $60 price target.

Morgan Stanley ( MS) estimates cut at Barclays MS 2010 and 2011 EPS estimates trimmed to $2.43 and $3.33, respectively. Barclays noted weaker trading revenues. Reiterate Equal Weight rating and $34 target.

Micron ( MU) estimates upped at UBS. MU estimates were increased through 2011. Strong demand should drive higher near-term results. Neutral rating and $10.50 price target.

Netflix ( NFLX) estimates, target boosted at FBR. Shares of NFLX now seen reaching $85. Estimates also raised, as the company should continue to deliver subscriber and margin growth. Outperform rating.

Nvidia ( NVDA) estimates, target raised at Citigroup. Shares of NVDA now seen reaching $24. Estimates were also boosted, following positive channel checks. Buy rating.

Research in Motion ( RIMM) estimates increased at Kaufman through 2011. Company will likely post strong earnings, driven by sales of the Curve and Bold devices. Buy rating.
This article was written by a staff member of